Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?

Immunocore’s IMCR sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or metastatic uveal melanoma (mUM), has been witnessing strong demand. Currently, the company’s top line solely comprises worldwide net product sales of Kimmtrak.

Since its approval and launch, Kimmtrak has established itself as the standard of care for eligible patients with metastatic uveal melanoma in most markets where it has been launched. The drug continues to witness healthy adoption, supported by increasing physician awareness, broader reimbursement coverage and geographic expansion.

Kimmtrak continues to generate solid sales growth globally. In the first half of 2026, Kimmtrak sales rose 16% year over year to $222.6 million. The strong commercial performance of Kimmtrak is expected to continue through the rest of 2026.

The continued uptake of Kimmtrak provides Immunocore with a growing commercial revenue base and supports the company's ability to fund investments in its broader pipeline.

Kimmtrak Label Expansion Could Be a Key Catalyst for IMCR

Several label expansion studies evaluating Kimmtrak both as monotherapy and in combination with other therapies are currently ongoing, targeting other settings for melanoma indications. Kimmtrak's growth prospects could extend beyond its current indication.

The registrational phase III TEBE-AM study is evaluating Kimmtrak as monotherapy and in combination with Merck’s MRK PD-L1 inhibitor Keytruda (pembrolizumab) versus a control arm in previously treated advanced cutaneous melanoma. The primary endpoint of the study is overall survival. Top-line data from the same might be announced as early as the end of 2026.

Positive results could support an expansion of Kimmtrak's addressable patient population and provide an additional catalyst for IMCR stock.

Merck’s biggest revenue driver, Keytruda, is approved for several types of cancer indications. MRK recorded $16.40 billion in Keytruda sales in the first half of 2026, up 4.2% year over year.

Beyond Kimmtrak, Immunocore is advancing a diversified pipeline of ImmTAC candidates across multiple oncology indications. The company is developing brenetafusp, in combination with Bristol Myers’ BMY blockbuster cancer drug, Opdivo (nivolumab), in the registrational phase III PRISM-MEL-301 study for treating first-line advanced cutaneous melanoma.

Brenetafusp is also being investigated in early-to-mid-stage studies both as monotherapy and as combination therapy in multiple tumor types, including ovarian cancer and non-small cell lung cancer.

BMY’s Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $4.63 billion in Opdivo sales in the first half of 2026, down 3.9% year over year.

IMCR Share Price Performance, Valuation & Estimates

Shares of Immunocore have risen 5.5% year to date compared with the industry’s growth of 12.1%.

Image Source: Zacks Investment Research

Going by the price/sales ratio, IMCR shares currently trade at 3.60X forward sales, higher than the industry’s average of 1.93X but lower than its mean of 9.37X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 earnings per share has moved up from 6 cents to 13 cents while the same for 2027 has declined from 65 cents to 48 cents over the past 30 days.

Image Source: Zacks Investment Research

IMCR’s Zacks Rank

Immunocore currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research